Treatment of Early-Stage Non-Small Cell Lung Cancer
| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Physician Assistant |
| Target Specialties: | Oncology |
| Credits Available: | 4.50 AMA PRA Category 1 Credit™ & 4.50 MOC points |
Immunotherapy, which has demonstrated benefits in advanced and metastatic settings, is moving into early non-small cell lung cancer treatment, expanding options for patients with resected or resectable early-stage non-small cell lung cancer. This rapid evolution of the early NSCLC treatment landscape, while exciting, has created clinical challenges as health care providers struggle with translating these clinical trial results into real-world clinical practices in the adjuvant and neoadjuvant settings. This educational initiative establishes impactful small group interactions among oncology care providers that will, through a variety of collaborative educational experiences, help them optimize the care of their patients with early-stage NSCLC.
CME/CE Accreditation Information
Itinerary
Part 1
The following questions are designed to assess your knowledge and practice of patients with early-stage non-small cell lung cancer.
This module will cover key trial updates for immunotherapies in the neoadjuvant or perioperative treatment of NSCLC.
This module will cover key trial updates for immunotherapies in the adjuvant treatment of NSCLC
This module will cover the recognition and management of immune-related adverse events from immunotherapies in the treatment of NSCLC.
The following questions are designed to assess your gained knowledge and practice of patients with early-stage non-small cell lung cancer.
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with early-stage NSCLC.
Part 2
62 yo female with a new diagnosis of stage 3A NSCLC (mediastinal LN involvement). On treatment, develops irAE of pneumonitis.
68 yo male with a new diagnosis of stage 2A NSCLC (with no nodal involvement). Requires further consideration for neoadjuvant/perioperative vs. adjuvant therapy.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with Early-Stage Non-Small Cell Lung Cancer.
During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.
Interested in becoming a Group Leader?
Experts in the management of patients with early-stage non-small cell lung cancer. Apply Now
